Use of Ebola Vaccine: Expansion of Recommendations of the Advisory Committee on Immunization Practices to Include two Additional Populations — United States, 2021

Jason H. Malenfant, MD; Allison Joyce, MSc; Mary J. Choi, MD; Caitlin M. Cossaboom, DVM, PhD; Amy N. Whitesell, MPH; Brian H. Harcourt, PhD; Robert L. Atmar, MD; Julie M. Villanueva, PhD; Beth P. Bell, MD; Christine Hahn, MD; Jamie Loehr, MD; Richard T. Davey, MD; Armand Sprecher, MD; Colleen S. Kraft, MD; Trevor Shoemaker, PhD; Joel M. Montgomery, PhD; Rita Helfand, MD; Inger K. Damon, MD, PhD; Sharon E. Frey, MD; Wilbur H. Chen, MD


Morbidity and Mortality Weekly Report. 2022;71(8):290-292. 

In This Article


Ebola virus, species Zaire ebolavirus, is the most lethal of the four viruses that cause EVD in humans, with case fatality rates of 70%–90% when untreated.[2] The virus is highly transmissible and can be found in all body fluids of an infected person.[3–5] If untreated, death from EVD can be rapid, usually occurring 7–10 days after the onset of symptoms.[6–9]